Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01023750 · ClinicalTrials.gov registry record
Predictors of Response to Fenofibrate
A clinical trial of Insulin Resistance and Hypertriglyceridemia, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 39
- Enrollment target
- 1
- Study location
NCT01023750 is a study of Insulin Resistance and Hypertriglyceridemia that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 39 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01023750, a study of Insulin Resistance and Hypertriglyceridemia, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Fenofibrate is one of the best options for treating hypertriglyceridemia. In the majority of patients, fenofibrate lowers triglycerides (TG) by 24-55% and improves HDL- and LDL-cholesterol. However, the response to fenofibrate is highly variable and currently there are no screening tests to identify poor responders. Genetic and environmental factors may explain the high variability in response. Although exploratory in nature, this study is of clinical and public health importance because prediction of drug response among those with hypertriglyceridemia is clinically challenging and fenofibrate prescription costs are large ($90 to $130/patient/month); targeting the responsive patients at the outset will help improve treatment outcomes at a lower cost. If successful, the investigators will propose to conduct a large, randomized trial on the effect of pre-prescription genotyping on fenofibrate response.
Conditions Studied
Interventions
- DRUG Fenofibrate
Study Locations (1)
Alabama
- UAB Kirklin Clinic - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01023750
The ClinicalTrials.gov registry entry for NCT01023750 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (84% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which Fenofibrate is the first listed.
NCT01023750 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT01023750 about?
NCT01023750 is a clinical study titled "Predictors of Response to Fenofibrate". Fenofibrate is one of the best options for treating hypertriglyceridemia. In the majority of patients, fenofibrate lowers triglycerides (TG) by 24-55% and improves HDL- and LDL-cholesterol. However, the response to fenofibrate is highly variable and currently there are no screening tests to identify...
What is the current status of trial NCT01023750?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2010-01. Estimated completion is 2012-07.
What conditions does trial NCT01023750 study?
This clinical trial studies the following conditions: Insulin Resistance, Hypertriglyceridemia.
What interventions are being tested in trial NCT01023750?
The interventions under investigation include: Fenofibrate (DRUG).
Who is sponsoring clinical trial NCT01023750?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01023750 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Small Extracellular Vesicles and Insulin Action
RECRUITING · NA
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.